1609 completed, 505 terminated, 496 recruiting, 464 unknown. 3697 Phase 2, 974 Phase 1, 77 Phase 3.
Follow Lymphoma: new trials by email Literature Review of Lymphoma trials Research Report on Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi-CAR-T Cells Targeting B Cell Lymphomas 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 11 | 2027-06-01 | 2026-11-02 |
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma golcadomide, Obinutuzumab, Polatuzumab - Multi Center, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-04-29 | 2026-11-05 |
| Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial Polatuzumab Vedotin, Acalabrutinib, Mosunetuzumab - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | University of Washington | 27 | 2027-03-01 | 2026-11-02 |
| Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma Epcoritamab, Observation - Randomized, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2027-02-12 | 2026-11-02 |
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Not yet recruiting | German Cancer Research Center | 216 | 2027-02-01 | 2026-10-22 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Ceritinib Treatment for Recurrent Meningiomas Ceritinib - Recurrent Meningioma, Grade I and Grade II | Phase 2 | Not yet recruiting | Kevin Petrecca | 10 | 2027-01-01 | 2026-10-23 |
| Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 70 | 2027-01-01 | 2026-09-30 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Washington University School of Medicine | 24 | 2026-12-31 | 2026-11-05 |
| Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma Fludarabine, Cyclophosphamide, CD70.CAR NK Cells - Large B-cell Lymphoma, Hodgkin Lymphoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 100 | 2026-12-28 | 2026-07-15 |
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma SYS6055 - Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd | 384 | 2026-12-15 | 2026-10-29 |
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 470 | 2026-12-13 | 2026-11-05 |
| MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy - Diffuse Large B-Cell Lymphoma | Phase 2 | Not yet recruiting | University of Nebraska | 50 | 2026-12-12 | 2026-11-06 |
| REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) REGN9220, Odronextamab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 36 | 2026-12-07 | 2026-10-21 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
Showing 20 of 3697. Sign in to see all of them.
Lymphoma, Non-Hodgkin (1002) · Lymphoma, Large B-Cell, Diffuse (875) · Lymphoma, Follicular (719) · Lymphoma, Mantle-Cell (604) · Hodgkin Disease (590) · Leukemia, Lymphocytic, Chronic, B-Cell (477) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (422) · Burkitt Lymphoma (419) · Lymphoma, B-Cell, Marginal Zone (393) · Leukemia (380) · Recurrence (375) · Lymphoma, B-Cell (329) · Multiple Myeloma (322) · Leukemia, Myeloid, Acute (267)
Neoplasms by Histologic Type (3681) · Hemic and Lymphatic Diseases (3646) · Immune System Diseases (3614) · Immunoproliferative Disorders (3613) · Lymphatic Diseases (3610) · Lymphoproliferative Disorders (3590) · Neoplasms (3580) · Lymphoma, Non-Hodgkin (1945) · Lymphoma, B-Cell (1140) · Hematologic Diseases (1101) · Pathological Conditions, Signs and Symptoms (925) · Pathologic Processes (903) · Disease Attributes (849) · Leukemia, Lymphoid (741)
Rituximab (755) · Cyclophosphamide (639) · Etoposide (309) · Doxorubicin (303) · Vincristine (300) · Prednisone (267) · Cytarabine (205) · Filgrastim (191) · Lenalidomide (190) · fludarabine (181) · fludarabine phosphate (176) · Methotrexate (172) · Dexamethasone (154) · Melphalan (138) · Radiotherapy (136)
National Cancer Institute (NCI) (195) · M.D. Anderson Cancer Center (179) · Memorial Sloan Kettering Cancer Center (95) · Fred Hutchinson Cancer Center (71) · City of Hope Medical Center (51) · Ruijin Hospital (43) · Sun Yat-sen University (42) · Alliance for Clinical Trials in Oncology (38) · Fondazione Italiana Linfomi - ETS (37) · Northwestern University (34) · Hoffmann-La Roche (33) · Masonic Cancer Center, University of Minnesota (33) · University of Washington (32) · Novartis Pharmaceuticals (31) · Chinese PLA General Hospital (30)
United States (2116) · China (599) · France (302) · Italy (284) · United Kingdom (230) · Germany (226) · Spain (222) · Canada (221) · Australia (171) · South Korea (163) · Belgium (131) · Poland (103) · Netherlands (82) · Japan (81) · Israel (73)
Ajay Gopal (12) · Craig Moskowitz, MD (11) · Brenda Sandmaier (9) · Tanya Trippett, MD (9)
PMID 34515338, PMID 41671463, PMID 35622074, PMID 40135712, PMID 40550489, PMID 31401903, PMID 32632956, PMID 32499241, PMID 39319495, PMID 23834234, PMID 34398557, PMID 40802906, PMID 17242396, PMID 21403127, PMID 22430088, PMID 23065508, PMID 23524640, PMID 26373676, PMID 27282998, PMID 30125215, PMID 30620669, PMID 31050355, PMID 32770353, PMID 34780125, PMID 35787017, PMID 35882475, PMID 37981564, PMID 38551807, PMID 40156952, PMID 40472301, PMID 18997171, PMID 19179301, PMID 19451441, PMID 21527516, PMID 22045986, PMID 23753028, PMID 24224624, PMID 24443277, PMID 24652992, PMID 24862638, PMID 25381051, PMID 25795722, PMID 26755709, PMID 27209293, PMID 28054442, PMID 28925994, PMID 28974506, PMID 29437592, PMID 30501490, PMID 30518502
2023 (44), U10CA180820 (40), P30CA015704 (37), P30CA033572 (37), 2015 (30), 2018 (25), U10CA031946 (25), 2017 (24), U10CA032102 (24), U10CA180886 (23), 2014 (22), 2016 (22), U24CA196172 (21), P30CA015083 (20), P30CA016672 (18)